Axa S.A. Buys 17,493 Shares of Exact Sciences Corporation $EXAS

Axa S.A. increased its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 3.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 574,143 shares of the medical research company’s stock after buying an additional 17,493 shares during the period. Axa S.A. owned 0.30% of Exact Sciences worth $30,510,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. National Pension Service grew its position in shares of Exact Sciences by 75.1% in the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 292 shares during the last quarter. SVB Wealth LLC bought a new stake in Exact Sciences in the 1st quarter valued at $30,000. True Wealth Design LLC grew its holdings in Exact Sciences by 951.8% in the 2nd quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock valued at $31,000 after buying an additional 533 shares in the last quarter. Country Trust Bank acquired a new position in Exact Sciences in the 2nd quarter valued at $32,000. Finally, Bessemer Group Inc. increased its position in Exact Sciences by 1,980.6% during the 2nd quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock worth $34,000 after buying an additional 614 shares during the period. 88.82% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Jacob A. Orville sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total value of $375,000.00. Following the completion of the transaction, the executive vice president owned 23,237 shares of the company’s stock, valued at $1,742,775. This represents a 17.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the director directly owned 57,962 shares in the company, valued at approximately $3,477,720. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 9,858 shares of company stock worth $695,289. Corporate insiders own 1.20% of the company’s stock.

Exact Sciences Trading Up 0.3%

Shares of EXAS stock opened at $101.25 on Wednesday. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $101.87. The stock’s fifty day moving average price is $74.33 and its two-hundred day moving average price is $59.34. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.44 and a current ratio of 2.72. The company has a market cap of $19.18 billion, a PE ratio of -19.03, a P/E/G ratio of 12.46 and a beta of 1.42.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.11. The business had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a positive return on equity of 1.67% and a negative net margin of 32.01%.Exact Sciences’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.21) EPS. Equities analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of recent research reports. Stifel Nicolaus reaffirmed a “hold” rating and set a $105.00 price target (up from $80.00) on shares of Exact Sciences in a research report on Friday, November 28th. BTIG Research cut shares of Exact Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 20th. Robert W. Baird set a $105.00 price target on shares of Exact Sciences in a research report on Thursday, November 20th. Craig Hallum downgraded Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price target on the stock. in a research report on Friday, November 21st. Finally, Citigroup lowered Exact Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 20th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, nineteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $85.00.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.